RxDoctor Payments Data

Nazarica Ricafrente

Family · Monterey Park, CANPI 1427435395

Payments from drug & device makers

$4,334in general payments, 2019–2025

Across 230 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Ardelyx, Inc.$630
  • Madrigal Pharmaceuticals$302
  • Ironwood Pharmaceuticals, Inc$270
  • Redhill Biopharma Inc.$253
  • Johnson & Johnson$221
  • plus $725 from 14 others

What the payments were for

  • Food & beverage$4,24398%
  • Education$912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,334 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$47,559
Medicare patients
312
Services billed
466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin79$244,093
CreonLipase/Protease/Amylase63$142,912
LinzessLinaclotide206$126,613
Mesalamine101$35,532
IbsrelaTenapanor Hcl18$33,841
Dexlansoprazole DrDexlansoprazole62$17,055
TaliciaOmeprazole/Amoxicill/Rifabutin14$11,228
Esomeprazole Magnesium158$8,642
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl481$7,648
Mesalamine ErMesalamine13$7,449
SutabSod Sulf/Pot Chloride/Mag Sulf46$7,095
Famotidine825$6,665
Mesalamine DrMesalamine22$5,631
Tetracycline Hcl42$5,387
Lactulose399$5,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$175$269,525269 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,933$244,09379 claims
Ardelyx, Inc.Ibsrela$630$33,84118 claims
Redhill Biopharma Inc.Talicia$253$11,22814 claims
Braintree Laboratories, Inc.Sutab$27$7,09546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Monterey Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →